Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma

T. M. Graff, A. K. Singavi, W. Schmidt, D. Eastwood, W. R. Drobyski, M. Horowitz, Jeanne Palmer, M. Pasquini, D. J. Rizzo, W. Saber, P. Hari, T. S. Fenske

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Autologous hematopoietic cell transplantation (Auto-HCT) is commonly an in-patient procedure. However, Auto-HCT is increasingly being offered on an outpatient basis. To better characterize the safety of outpatient Auto-HCT, we compared the outcome of 230 patients who underwent Auto-HCT on an in-patient vs outpatient basis for myeloma or lymphoma within a single transplant program. All outpatient transplants occurred in a cancer center day hospital. Hematopoietic recovery occurred earlier in the outpatient cohort, with median time to neutrophil recovery of 10 vs 11 days (P<0.001) and median time to platelet recovery of 19 vs 20 days (P=0.053). Fifty-one percent of the outpatient cohort never required admission, with this percentage increasing in later years. Grade 3-4 non-hematologic toxicities occurred in 29% of both cohorts. Non-relapse mortality at 1 year was 0% in the outpatient cohort and 1.5% in the in-patient cohort (P=0.327). Two-year PFS was 62% for outpatient vs 54% for in-patient (P=0.155). One-and two-year OS was 97% and 83% for outpatient vs 91% and 80% for in-patient, respectively (P=0.271). We conclude that, with daily outpatient evaluation and aggressive supportive care, outpatient Auto-HCT can result in excellent outcomes for myeloma and lymphoma patients.

Original languageEnglish (US)
Pages (from-to)947-953
Number of pages7
JournalBone Marrow Transplantation
Volume50
Issue number7
DOIs
StatePublished - Jul 3 2015

Fingerprint

Cell Transplantation
Multiple Myeloma
Lymphoma
Outpatients
Safety
Transplants
Ambulatory Care
Neutrophils
Blood Platelets
Mortality

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Graff, T. M., Singavi, A. K., Schmidt, W., Eastwood, D., Drobyski, W. R., Horowitz, M., ... Fenske, T. S. (2015). Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplantation, 50(7), 947-953. https://doi.org/10.1038/bmt.2015.46

Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. / Graff, T. M.; Singavi, A. K.; Schmidt, W.; Eastwood, D.; Drobyski, W. R.; Horowitz, M.; Palmer, Jeanne; Pasquini, M.; Rizzo, D. J.; Saber, W.; Hari, P.; Fenske, T. S.

In: Bone Marrow Transplantation, Vol. 50, No. 7, 03.07.2015, p. 947-953.

Research output: Contribution to journalArticle

Graff, TM, Singavi, AK, Schmidt, W, Eastwood, D, Drobyski, WR, Horowitz, M, Palmer, J, Pasquini, M, Rizzo, DJ, Saber, W, Hari, P & Fenske, TS 2015, 'Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma', Bone Marrow Transplantation, vol. 50, no. 7, pp. 947-953. https://doi.org/10.1038/bmt.2015.46
Graff, T. M. ; Singavi, A. K. ; Schmidt, W. ; Eastwood, D. ; Drobyski, W. R. ; Horowitz, M. ; Palmer, Jeanne ; Pasquini, M. ; Rizzo, D. J. ; Saber, W. ; Hari, P. ; Fenske, T. S. / Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. In: Bone Marrow Transplantation. 2015 ; Vol. 50, No. 7. pp. 947-953.
@article{1b53afd1ebe94d10b699fe4178868bf4,
title = "Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma",
abstract = "Autologous hematopoietic cell transplantation (Auto-HCT) is commonly an in-patient procedure. However, Auto-HCT is increasingly being offered on an outpatient basis. To better characterize the safety of outpatient Auto-HCT, we compared the outcome of 230 patients who underwent Auto-HCT on an in-patient vs outpatient basis for myeloma or lymphoma within a single transplant program. All outpatient transplants occurred in a cancer center day hospital. Hematopoietic recovery occurred earlier in the outpatient cohort, with median time to neutrophil recovery of 10 vs 11 days (P<0.001) and median time to platelet recovery of 19 vs 20 days (P=0.053). Fifty-one percent of the outpatient cohort never required admission, with this percentage increasing in later years. Grade 3-4 non-hematologic toxicities occurred in 29{\%} of both cohorts. Non-relapse mortality at 1 year was 0{\%} in the outpatient cohort and 1.5{\%} in the in-patient cohort (P=0.327). Two-year PFS was 62{\%} for outpatient vs 54{\%} for in-patient (P=0.155). One-and two-year OS was 97{\%} and 83{\%} for outpatient vs 91{\%} and 80{\%} for in-patient, respectively (P=0.271). We conclude that, with daily outpatient evaluation and aggressive supportive care, outpatient Auto-HCT can result in excellent outcomes for myeloma and lymphoma patients.",
author = "Graff, {T. M.} and Singavi, {A. K.} and W. Schmidt and D. Eastwood and Drobyski, {W. R.} and M. Horowitz and Jeanne Palmer and M. Pasquini and Rizzo, {D. J.} and W. Saber and P. Hari and Fenske, {T. S.}",
year = "2015",
month = "7",
day = "3",
doi = "10.1038/bmt.2015.46",
language = "English (US)",
volume = "50",
pages = "947--953",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma

AU - Graff, T. M.

AU - Singavi, A. K.

AU - Schmidt, W.

AU - Eastwood, D.

AU - Drobyski, W. R.

AU - Horowitz, M.

AU - Palmer, Jeanne

AU - Pasquini, M.

AU - Rizzo, D. J.

AU - Saber, W.

AU - Hari, P.

AU - Fenske, T. S.

PY - 2015/7/3

Y1 - 2015/7/3

N2 - Autologous hematopoietic cell transplantation (Auto-HCT) is commonly an in-patient procedure. However, Auto-HCT is increasingly being offered on an outpatient basis. To better characterize the safety of outpatient Auto-HCT, we compared the outcome of 230 patients who underwent Auto-HCT on an in-patient vs outpatient basis for myeloma or lymphoma within a single transplant program. All outpatient transplants occurred in a cancer center day hospital. Hematopoietic recovery occurred earlier in the outpatient cohort, with median time to neutrophil recovery of 10 vs 11 days (P<0.001) and median time to platelet recovery of 19 vs 20 days (P=0.053). Fifty-one percent of the outpatient cohort never required admission, with this percentage increasing in later years. Grade 3-4 non-hematologic toxicities occurred in 29% of both cohorts. Non-relapse mortality at 1 year was 0% in the outpatient cohort and 1.5% in the in-patient cohort (P=0.327). Two-year PFS was 62% for outpatient vs 54% for in-patient (P=0.155). One-and two-year OS was 97% and 83% for outpatient vs 91% and 80% for in-patient, respectively (P=0.271). We conclude that, with daily outpatient evaluation and aggressive supportive care, outpatient Auto-HCT can result in excellent outcomes for myeloma and lymphoma patients.

AB - Autologous hematopoietic cell transplantation (Auto-HCT) is commonly an in-patient procedure. However, Auto-HCT is increasingly being offered on an outpatient basis. To better characterize the safety of outpatient Auto-HCT, we compared the outcome of 230 patients who underwent Auto-HCT on an in-patient vs outpatient basis for myeloma or lymphoma within a single transplant program. All outpatient transplants occurred in a cancer center day hospital. Hematopoietic recovery occurred earlier in the outpatient cohort, with median time to neutrophil recovery of 10 vs 11 days (P<0.001) and median time to platelet recovery of 19 vs 20 days (P=0.053). Fifty-one percent of the outpatient cohort never required admission, with this percentage increasing in later years. Grade 3-4 non-hematologic toxicities occurred in 29% of both cohorts. Non-relapse mortality at 1 year was 0% in the outpatient cohort and 1.5% in the in-patient cohort (P=0.327). Two-year PFS was 62% for outpatient vs 54% for in-patient (P=0.155). One-and two-year OS was 97% and 83% for outpatient vs 91% and 80% for in-patient, respectively (P=0.271). We conclude that, with daily outpatient evaluation and aggressive supportive care, outpatient Auto-HCT can result in excellent outcomes for myeloma and lymphoma patients.

UR - http://www.scopus.com/inward/record.url?scp=84934795677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934795677&partnerID=8YFLogxK

U2 - 10.1038/bmt.2015.46

DO - 10.1038/bmt.2015.46

M3 - Article

C2 - 25867651

AN - SCOPUS:84934795677

VL - 50

SP - 947

EP - 953

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -